Dear all,
A warm welcome to our very first Vimian-wide newsletter! The idea of a quarterly newsletter to all employees originates from one of the working groups in our leadership program. I hope you will find it inspiring to learn more about the whole Vimian world!
We are leaving a busy start to the fall behind us with lots of trade shows, educational events and member days I would like to thank all of you for your hard work, passion and commitment to improving animal health!
Our business is trending positively with good growth driven by strong momentum in Nextmune and VetFamily. In Movora, we have seen healthy growth in Europe and Asia-Pacific and a recovery in North America, but we continue to be challenged by a tough market for our orthopedic implants in US. The Movora team is deploying numerous actions, and I am confident that we are on the right track and that the market eventually will recover. In Indical, we are working hard with the roll-out of Ovacyte, our new exciting AI enabled diagnostics tool for pets.
Strategy remains the same
On 2 October, we had a good strategy meeting with our Board that were all highly supportive of our plans. Overall, we remain focused on global niches of the animal health market where there are clear unmet medical needs and where we can make a true difference to improve animal health and create a better life for animals and their families. We achieve this by what we call reach; i.e. making our products and services available in more markets and channels, through innovation; by making new innovative treatments available on the market and through education; by educating the veterinary community so they can perform best-in-class care. We welcome new businesses to our family, leverage their know-how and make those products accessible to more vets and pet owners around the world. Currently, we are ramping up our efforts on acquisitions and expect to welcome more entrepreneurial-led, successful businesses over the years to come.
Creating a great place to work
Integrated into the core of our business is our sustainability agenda focused on our people, animal health and the planet. Creating a great place to work will be key to our success and I would like to thank everyone for taking the time to take part in our employee survey in September! Your input is highly valuable to us, and I read all the open comments that you have provided in the survey so we can focus on what really matters to you. I expect every team leader to set aside time to discuss the results and the plan forward with the team.
Together, we will create positive change – and improve animal health for better lives.
-- Carl-Johan Zetterberg Boudrie, CFO and interim CEO
Employee Survey
Great engagement across Vimian
Our latest employee survey shows strong engagement across Vimian, with an outstanding 97% participation rate and high scores in autonomy and inclusion. Together, we’re shaping an even better place to work.
With an impressive 97% participation rate, our latest employee survey shows strong engagement and a shared commitment to making Vimian a great place to work. Thank you to everyone who took the time to share your thoughts — your feedback truly helps shape our culture and priorities. The results show that we continue to perform strongly on autonomy and inclusion across all segments, reflecting a workplace where people feel trusted, valued, and part of a supportive environment. Our eNPS of 30 indicates a healthy level of engagement, with more employees recommending Vimian as a great place to work than not. However, the survey also highlights clarity as an area for improvement — an opportunity for us to strengthen communication and shared understanding across the Group. The next step is for all teams to review their results together, celebrate what’s working well, and identify a few concrete areas to focus on improving over time.
Highlights:
- 97% participation rate
- eNPS: 30 (target: 50)
- Top drivers: autonomy and inclusion
Quarterly innovation highlights
Nextmune launches Peptivet® 4
Nextmune launched 21 new products during the third quarter. Peptivet® 4, launched earlier this year in its originating country, Italy, was introduced to additional European markets during Q3.
Peptivet® 4 is an advanced eudermic otological solution effectively supporting the reduction of bacterial and Malassezia fungus growth in dogs and cats with otitis. Peptivet® 4 exploites the synergic action of four molecules – chlorhexidine digluconate, cyclodextrins and synthetic peptides ARTA0002 and AMP2041.
Thanks to its composition, Peptivet® 4 offers dual benefits – it provides immediate action, thanks to the combination of chlorhexidine digluconate and free peptides as well as prolonged action, thanks to the gradual release of peptides complexed within the cyclodextrins.
Movora advances orthopedics
While hip replacements for animals are well-established, prosthetic knee, elbow, and ankle joints are gaining momentum across Europe and the US.
ECVS Diplomate Philipp Schmierer from Tierklinik Posthausen recently joined Sarah Israel, DVM, DACVS, Ericka Jaramillo, DVM, Joint Replacement Fellow Candidate, and the VROC surgeons at the state-of-the-art VROC facility in Austin, Texas, for intensive training in cutting-edge total joint replacement procedures led by Laurent Guiot, DVM, DACVS.
We’re proud to see Movora partner with the surgeons moving veterinary care forward. Dr. Schmierer plans for the first surgeries in Germany using the advanced knee, elbow, and ankle prostheses from BioMedtrix, making available completely new treatment options for pets worldwide.
Cross-segment collaboration
Movora, iM3 and Vertical Vet in joint education event in Texas
Movora, iM3 and VerticalVet joined forces in Austin, Texas, for a hands-on education event for veterinarians — showcasing collaboration in action and advancing knowledge in both orthopaedics and dentistry.
Movora, iM3 and VerticalVet US recently co-hosted a continuing education event in Austin, Texas, offering valuable learning opportunities for general practitioners. The programme included a practical session on dental cleaning techniques led by iM3 and a hands-on workshop on stifle joint management featuring Movora’s new Ortho-Sta product.
The event brought together expertise from several parts of Vimian to advance veterinary medicine and improve animal health.
Collaboration in action: VetFamily and Nextmune join forces to engage equine clinics
In Sweden, VetFamily saw an opportunity to strengthen its engagement with equine clinics. To better understand their needs, offer tailored value, and show how the VetFamily concept can help these clinics grow and develop.
Leading the initiative was Ulrika Håkansson from VetFamily, who reached out to Magdalena Neteborn and Peter Bjurling at Nextmune to explore potential collaboration. Together, they identified a common area of focus: allergy testing and treatment in horses, including Nextmune’s PAX product line.
The starting point was clear: how can we engage our member clinics more in allergy testing and treatment in general, and with Nextmune’s expertise specifically?
The result was a targeted educational series developed jointly by VetFamily and Nextmune, featuring veterinarians, nurses, care staff, assistants, and receptionists from VetFamily’s member clinics. Alongside the training, Nextmune’s allergy and dermatology products were highlighted across VetFamily’s communication channels, ensuring both education and visibility went hand in hand.
Ulrika emphasises that the key to success has been an open and transparent dialogue with Magdalena and Peter: “We’ve discussed both opportunities and challenges very honestly. That openness made it possible to find the right ideas and avoid the ones that wouldn’t work.”
This collaboration is a great example of the power of partnership within Vimian Group, combining expertise, relationships, and shared purpose to create real value for clinics and veterinarians.
BOVA and iM3 join forces to launch Oralvive™
BOVA UK and iM3 have launched Oralvive™, a breakthrough Hyaluronic Acid 0.8% gel supporting oral tissue and bone regeneration in animals.
Oralvive™ marks a major milestone in collaboration and innovation within Vimian. Developed jointly by BOVA UK and iM3, the Hyaluronic Acid 0.8% gel supports advanced oral tissue and bone regeneration in animals. iM3 identified the market opportunity, while BOVA transformed the idea into a viable, approved product through its formulation and manufacturing expertise.
With a coordinated global launch across the US, Europe, and Australia, Oralvive™ is set to improve oral healing outcomes for animals worldwide.
Quarterly segment highlights
Movora
- In August, Movora welcomed Christopher Lutter as new North America Vice President.
- Movora won the 2025 B2B Excellence Award, marking Movora’s third major MarCom award to date.
- Video Alert: Hear some of the world’s most well-renowned surgeons speak about Movora’s impact
- iM3 USA expands to new West Coast site. The team has opened a 25,000 sq. ft. facility that combines warehousing and production under one roof. The space supports current operations while allowing for growth over the next decade, with potential to sublet areas to other Vimian segments – contact craig.evans@im3dental.com for details.
- Maggie Burley, who provides education and client support to clinics across Australia and New Zealand, received the Excellence in Veterinary Education Award from the Academy ofVeterinary Dental Technicians for her outstanding contributions to advancing veterinary dentistry.
VetFamily
- VetFamily Norway recently marked its 10-year anniversary, bringing together more than 180 members and partners for a day filled with conversations and presentations — a celebration of community and collaboration.
- VetFamily Global Team Conference 2025: In early November, over 130 VetFamily colleagues from Europe, the Americas, and Australia will gather for a three-day global conference. The event will also feature the annual VetFamily Awards, including the Vimian Colleague of the Year category, with six inspiring nominees from across the group — celebrating an individual who brings VetFamily’s values to life and helps strengthen the clinic community. The six nominees are; Pauline Ruggiero from INDICAL, Joana Leite and Peter Bjurling from Nextmune, Maria Nanhed and Fabienne Zihlmann from Movora, and Linn Anstérus from Vimian.
Nextmune
- Nextmune active at leading industry events. Nextmune attended the equine BEVA Congress in UK – where Bova was awarded Best Stand – and was gold sponsor at the European Veterinary Dermatology Congress in Bilbao, where the team presented Peptivet® 4 and PAX 2.0 (expected launch 2026).
- Nextmune launches new global website. In August, Nextmune unveiled its new website – a modern, user-friendly platform. The site offers a clear overview of Nextmune’s comprehensive product portfolio – check it out! www.nextmune.com
- Bova achieves sustainability award, for its ongoing commitment to environmental sustainability
Indical
- INDICAL hosted two successful and global webinars in Q3 with more than 1,000 registrations and 430 attendees.
- INDICAL joined DVG- Fachgruppe’s AVID event – a key platform to exchange knowledge, showcase work and engage with the German community.
- A successful parasitology session was held at the University of Veterinary Medicine in Vienna.